Penn Engineering Lab develops next-generation drug delivery technologies
Mike Mitchell's lab has numerous ongoing research partnerships to support new therapeutic solutions with commercial entities that were facilitated by PCI.
Carisma Therapeutics continues to thrive and expand
Penn and Carisma Therapeutics (Carisma) have strengthened the intellectual property portfolio covering this technology with the issuance of five additional patents in 2022.
Penn Medicine Co-Investment Program continues to thrive
Fiscal year 2022 saw the Co-Investment Program help launch and fund 2 new companies ViTToria Biotherapeutics and Dispatch Bio, as well as participate in follow-on rounds for Linnaeus Therapeutics, Car
CAR-T startup Vittoria Biotherapeutics launches
Vittoria Biotherapeutics' mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies.
PCI highlights innovation in Penn Robotics during Philly Tech Week
From May 6 - 12, PCI participated in the 12th annual Philly Tech Week, a conference hosted by Technical.ly Philly, to showcase some of the city's best technology and innovation.
Abrax Japan licenses technology from Penn
Abrax Japan entered into an exclusive licensing agreement for certain Penn-owned inventions relating to the therapeutic effects of thymic stromal lymphopoietin (TSLP).
FY22 President’s Innovation Prizes Awarded
Awarded annually, the President’s Innovation Prize empowers Penn students to design and undertake a post-graduation startup company that makes a positive, lasting difference in the world.
New ASSET Center
Penn Engineering’s newly formed ASSET (AI-enabled Systems: Safety, Explainablity and Trustworthiness) Center is part of Penn Engineering’s Innovation in Data Engineering & Science (IDEAS) Initiative.
Cleantech innovation for CO2 capture moves forward through Heirloom Carbon Technologies
PCI, along with Columbia University and the University of British Columbia, recently completed a license agreement with Heirloom Carbon Technologies.
IBA partners with Penn Medicine to develop flash therapy
IBA Worldwide, a technology company that develops particle accelerator technology, partnered with a team of faculty from Radiation Oncology at Penn Medicine led by Dr. James Metz.